TheTechno Optimist.

SignateraNatera—Natera presents 35 oncology studies at ASCO 2026, including three oral presentations on MRD-guided cancer careSignateraNatera—Japan's PMDA approves Signatera for colorectal cancer MRD testing, the first PMDA-approved MRD testSignateraNatera—FDA approves Signatera as companion diagnostic for muscle-invasive bladder cancer, the first MRD test to achieve this designationSignateraNatera—Natera reports record Q2 2026 results: 283,000 Signatera tests (+56% YoY), total revenue $753M (+38% YoY), guidance raised to $2.85-2.91B

Signatera

by NateraUS

Enable MRD-guided treatment decisions to optimize chemotherapy use and improve survival.

DeployStage 4 of 5

FDA CDx approved May 2026 (bladder); Japan approved June 2026 (colorectal); GALAXY trial ongoing.

Updated Jun 2026Checked 11 Oct0 updates this week

Milestones

Next · GALAXY prospective trial (colorectal cancer)
  1. FDA approval CDx for bladder cancerMay 2026Complete.
  2. Japan PMDA approval for colorectal cancerJun 2026Complete.
  3. European IVDR certification9 Jul 2026Complete.
  4. GALAXY prospective trial (colorectal cancer)Target 2026Current milestone.

Most important updates

Upcoming

  1. 2026GALAXY prospective trial (colorectal cancer) (next)
  2. 2027Potential FDA approval for additional cancer types
Primer